drugset / Trial / NCT02245438

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

NCT02245438

Phase 1 Terminated 52 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to characterize the effects of two dose combinations of Tipranavir (TPV)/Ritonavir (RTV) (TPV 750 mg/RTV 200 mg and TPV 500 mg/RTV 100 mg), administered twice-daily, on the pharmacokinetics of Norethindrone-Ethinyl Estradiol (NET/EE) 1 mg/ 0.035 mg administered as a single dose.

Timeline

Start
2002-05
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Norethindrone-Ethinyl Estradiol Unknown 0.035 mg
Subject Norethindrone-Ethinyl Estradiol Unknown 1 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg
Subject Tipranavir Small molecule 750 mg

Indications

No indication recorded.